CC 90003

Drug Profile

CC 90003

Alternative Names: CC-90003; ERK inhibitor - Celgene

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 05 Jun 2017 Updated safety, efficacy and pharmacokinetic data from a phase Ia trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) presented results of the trial at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 22 Aug 2016 Celgene terminates a phase Ia trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT02313012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top